Carnitine palmitoyltransferase-II inactivity promotes malignant progression of metabolic dysfunction-associated fatty liver disease via liver cancer stem cell activation

Figure 3 carnitine palmitoyl transferase-II in T cells or the mitochondrial membrane potential in metabolic dysfunction-associated fatty liver disease hepatocarcinogenesis. A: Ratios of blood CD3+ T cells to peripheral blood mononuclear cells; B: Blood CD3+ T cell percentages; C: Blood CD4+ T cell percentages; D: Blood CD8+ T cells; E: Carnitine palmitoyl transferase-II (CPT-II) was evaluated by Western blot analysis at specific concentrations; F: CPT-II in CD4+ T cells; G: CPT-II in CD8+ T cells; H: Mitochondrial membrane potential median fluorescence intensity (MFI) in blood CD3+ T cells; I: MFI in spleen CD4+ T cells; J: MFI in spleen CD8+ T cells. ^aP < 0.05, compared with the normal control group; NC: Normal control; HCC: Hepatocellular carcinoma; MAFL: Metabolic dysfunction-associated fatty liver; MASH: Metabolic dysfunction-associated steato-hepatitis; LC: Liver cirrhosis; CPT-II: Carnitine palmitoyl transferase-II.